In light of a recent publication showing pro-atherogenesis and dyslipidemia effects associated with ABCC6 deficiency in both ABCC6−/− mice and PXE patients [32], our data bring into question the cost/benefit ratio for the use of these drugs in PXE. The gene discussed is ABCC6; the disease is metabolic syndrome.